tiprankstipranks
Dr. Reddy’s Laboratories Reports Record Quarterly Growth
Company Announcements

Dr. Reddy’s Laboratories Reports Record Quarterly Growth

Dr Reddy’s Laboratories (RDY) has released an update.

Don't Miss our Black Friday Offers:

Dr. Reddy’s Laboratories reported a robust second quarter for FY25, showcasing a 17% year-over-year revenue growth, achieving their highest ever quarterly sales and profit before tax. The company highlighted its strategic acquisition of the NRT portfolio and a successful stock split, boosting investor confidence. A collaborative effort with Nestlé India further strengthens its nutraceuticals business, positioning Dr. Reddy’s for continued growth.

For further insights into RDY stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyDr. Reddy’s and Senores launch Ivermectin tablets USP, 3 mg in U.S.
TipRanks Auto-Generated NewsdeskDr. Reddy’s Labs to Engage with Investors in New York
TipRanks Auto-Generated NewsdeskDr. Reddy’s Receives USFDA Observations Post Inspection
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App